Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P42574 (
caspase-3
)
45,978
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Background:
Long non-coding RNA
Zinc finger E-box binding homeobox 2
(
ZEB2
) antisense RNA 1 (
ZEB2
-AS1
) has been shown to promote tumor progression. However, the clinical significance and fundamental function role of
ZEB2
-AS1
in osteosarcoma (OS) was poorly understood.
Methods:
The expression of
ZEB2
-AS1
was determined in tumor tissues and matched normal tissues from 67 OS patients using quantitative reverse transcriptase PCR analysis. Clinical value of
ZEB2
-AS1
was evaluated by Chi square test and Kaplan-Meier method. Cell proliferation was analyzed using CCK-8 assay, colony formation. Cell apoptosis status was determined by
caspase-3
activity assay. Cell migration, invasion and epithelial-mesenchymal transition (EMT) were investigated by scratch wound healing, transwell invasion assays and western blotting.
Results:
Clinical association analysis revealed that high
ZEB2
-AS1
expression correlated with tumor size, distant metastasis and poor prognosis of OS patients. Moreover,
ZEB2
-AS1
expression was identified as an independent prognostic factor for OS patients. Loss-of-function assays demonstrated that
ZEB2
-AS1
knockdown suppressed the proliferation and induced apoptosis in OS cells. In addition,
ZEB2
-AS1
knockdown inhibited cell migration, invasion, EMT of OS cells
in vitro
.
Conclusions:
Taken together, our data demonstrate that
ZEB2
-AS1
serves a putative oncogenic role and associates with unfavorable prognosis in OS.
...
PMID:The Long Noncoding RNA
ZEB2-AS1
Contributes to Proliferation and Epithelial-to-Mesenchymal Transition of Osteosarcoma. 3308 24
